Clinical trial · Interventional
Stereotactic Body Radiotherapy for Head and Neck Tumors
Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors
NCT01344356CI-TRIAL-00044595completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Angiofibroma of Head and Neck | — | UNRESOLVED | — |
| Chondrosarcoma of Head and Neck | — | UNRESOLVED | — |
| Chordoma of Head and Neck | — | UNRESOLVED | — |
| Head and Neck Sarcoma | Head and Neck Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Paraganglioma of Head and Neck | Head and Neck Paraganglioma | ALIAS | 0.90 |
| Salivary Gland Cancer | Malignant Salivary Gland Neoplasm | ALIAS | 0.90 |
| Squamous Cell Carcinoma of the Head and Neck | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| stereotactic body radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Benign Tumors
- description
- Benign head and neck tumors will be treated with SBRT
- interventionNames
- Radiation: stereotactic body radiotherapy
- type
- OTHER
- label
- Malignant Tumors
- description
- Malignant Head and Neck Tumors will be treated with SBRT.
- interventionNames
- Radiation: Stereotactic body radiotherapy
Primary outcomes (3)
- measure
- Local Control Rate
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient age \> 18 years * Zubrod performance status of 0-3 * Benign head and neck tumors such as paragangliomas, chordoma, chondrosarcoma * Malignant head and neck cancers such as invasive squamous cell carcinoma, adenocarcinoma, nasopharyngeal carcinoma, salivary gland cancers, and sarcoma * Signed study-specific consent form Exclusion Criteria: * Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females * Patients with psychiatric or addictive disorder that would preclude obtaining informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.